Creative Planning’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Creative Planning’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,000	Closed	-$3K	–	4359
2017 Q2	$3K	Hold	2,000	–	–	﹤0.01%	4248
2017 Q1	$5K	Hold	2,000	–	–	﹤0.01%	4003
2016 Q4	$5K	Hold	2,000	–	–	﹤0.01%	4008
2016 Q3	$6K	Hold	2,000	–	–	﹤0.01%	3839
2016 Q2	$6K	Hold	2,000	–	–	﹤0.01%	3578
2016 Q1	$6K	Sell	2,000 -3,000	-60%	-$9.79K	﹤0.01%	3533
2015 Q4	$20K	Buy	+5,000	New	+$23K	﹤0.01%	2865
2014 Q4	–	Sell	-306	Closed	-$2K	–	4439
2014 Q3	$2K	Hold	306	–	–	﹤0.01%	3731
2014 Q2	$2K	Sell	306 -48,777	-99%	-$549K	﹤0.01%	3571
2014 Q1	$1.17M	Buy	49,083 +48,683	+12,171%	+$706K	0.02%	323
2013 Q4	$4K	Hold	400	–	–	﹤0.01%	2950
2013 Q3	$5K	Hold	400	–	–	﹤0.01%	2761
2013 Q2	$5K	Buy	+400	New	+$5.39K	﹤0.01%	2574

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

CRC

Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning's ECYT Position: Q3 2017 in Review

Creative Planning sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2017, closing a stake of 2,000 shares — an estimated $3K sold.

Creative Planning first reported a position in ECYT in Q2 2013 and held it in 13 quarters. The position peaked at $1.17M in Q1 2014. 63 funds tracked by Wall St. Rank hold ECYT as of Q3 2017.

Creative Planning reported no remaining Endocyte, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 2,000 Endocyte, Inc. Common Stock shares in Q3 2017, an estimated $3K.
Creative Planning first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 13 quarters.
Creative Planning's Endocyte, Inc. Common Stock position peaked at $1.17M in Q1 2014.
63 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.